Form 4: Karyopharm Therapeutics Director Garen Bohlin Granted New Stock Options

Karyopharm Therapeutics Inc. Director Garen G. Bohlin was granted 4,600 nonstatutory stock options with an exercise price of $4.48 per share, vesting fully on May 28, 2026.

Summary

• Garen G. Bohlin, a Director of Karyopharm Therapeutics Inc. (KPTI), acquired 4,600 nonstatutory stock options.
• The transaction date for this grant was May 28, 2025.
• Each option has an exercise price of $4.48 per share.
• The options are for Common Stock of Karyopharm Therapeutics Inc.
• These options will vest as to 100% of the underlying shares on May 28, 2026.
• The expiration date for these options is May 27, 2035.
• All reported amounts reflect a one-for-fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns management incentives with shareholder interests, indicating continued commitment. It is generally viewed as neutral to slightly positive.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• The acquisition of options by an insider can signal confidence in the company's future performance.

Future Outlook

The document primarily reports a past transaction and does not provide a general future outlook for the company's operations or financial performance beyond the vesting schedule of the granted options.

Industry Context

This Form 4 filing details a routine insider equity compensation event, which is a common practice across all industries, including the biotechnology and pharmaceutical sectors where Karyopharm Therapeutics operates. Such grants are standard mechanisms to align the interests of directors and executives with long-term shareholder value.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if and when the options are exercised, but also increased alignment of the director's interests with the company's stock performance.
• Employees: No direct impact mentioned for general employees.

Next Steps

• The options granted to Garen G. Bohlin are scheduled to vest on May 28, 2026.
• Following vesting, the options can be exercised at any time until their expiration on May 27, 2035.

Key Dates

Keywords

Karyopharm Therapeutics, KPTI, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Nonstatutory Stock Option, Reverse Stock Split